Abstract OBJECTIVE: To evaluate the efficacy and safety of aripiprazole in the treatment of tic disorder when tiapride is used as a control. METHODS: Sixty-five children aged 6-14 years old with tic disorders were randomly assigned to two groups: aripiprazole (2.5-10 mg/d) and tiapride treatment (25- 400 mg/d). After 12 weeks treatment, the clinical efficacy was assessed by the Yale Global Tie Severity Scale (YGTSS) score and the adverse reactions were observed. RESULTS: The YGTSS score in both groups decreased from the second week of treatment. Compared with the tiapride treatment group, the aripirazole treatment group showed a more decreased YGTSS score ［(29±13)% vs (16±14)%; P0.05) 12 weeks after treatment. There were no significant differences in the incidence of adverse reactions between the aripiprazole and tiapride treatment groups and no severe adverse events were found in either group. CONCLUSIONS: Low dose aripiprazole is safe and effective for treatment of tic disorders in children, suggesting that it represents a new valid option for the treatment of tic disorder.［Chin J Contemp Pediatr, 2010, 12 (6):421-424］
LIU Yan-Yan,CHEN Yan-Hui,CHEN Hui et al. A control study of aripiprazole and tiapride treatment for tic disorders in children[J]. 中国当代儿科杂志, 2010, 12(06): 421-424.
LIU Yan-Yan,CHEN Yan-Hui,CHEN Hui et al. A control study of aripiprazole and tiapride treatment for tic disorders in children[J]. CJCP, 2010, 12(06): 421-424.
［4］Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis［J］. Prog Brain Res, 2008, 172:199-212.
［5］Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and dolescents with Tourette disorder or chronic Tic disorder［J］. J Child Adolesc Psychopharmacol, 2008, 18(2):197-205.
［6］Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole［J］. Hum Psychopharmacol, 2006, 21(7):447-453.
［7］Miranda CM, Castiglioni TC. Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients［J］. Rev Med Chil, 2007,135(6):773-776.
［8］American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision) ［M］. Washington, DC:American Psychiatric Association, 2000:1-943.
［9］Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity［J］. J Am Acad Child Adolesc Psychiatry, 1989, 28(4): 566-573.
［10］Kane JM. Optimizing pharmacotherapy to maximize outcome in schizophrenia［J］. J Clin Psychiatry, 2005, 66(1):122133.
［12］Ben Djebara M, Worbe Y, Schupbach M, Hartmann A. Aripiprazole: A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome［J］.Movement Disorders, 2008, 23(3):438-440.
［13］Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, et al. Case series on the use of aripiprazole for Tourette syndrome［J］. Int J Neuropsychopharmacol, 2005, 8(3):489-490.
